Stem cell-based therapy for myopic maculopathy: a new concept

Abstract

Myopia has reached epidemic proportions in the world, especially in East Asia. Pathologic myopia is an extreme type of high myopia that can cause irreversible blindness. Myopic maculopathy is one of the characteristics of pathologic myopia. Nowadays, limited treatments can preserve the visual outcome of these patients. We review the current treatment in practice for myopic maculopathy. Furthermore, based on the current stem cell-based therapy used in degenerative ocular diseases, we discuss a new concept of stem cell therapy for myopic maculopathy.

Keywords

Pathologic myopia / myopic maculopathy / stem cell

References

[1] FlitcroftDI,JonasJB.IMI - Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies.Invest Ophthalmol Vis Sci2019;60:M20-30 PMCID:PMC6735818

[2] Ohno-MatsuiK,YamashiroK.IMI pathologic myopia.Invest Ophthalmol Vis Sci2021;62:5 PMCID:PMC8083114

[3] HoldenBA,WilsonDA.Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050.Ophthalmology2016;123:1036-42

[4] WongTY,HughesR,MitchellP.Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review.Am J Ophthalmol2014;157:9-25.e12

[5] GrzybowskiA,TsubotaK,SawSM.A review on the epidemiology of myopia in school children worldwide.BMC Ophthalmol2020;20:27 PMCID:PMC6961361

[6] XuL,LiY.Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study.Ophthalmology2006;113:1134.e1-11

[7] LiangYB,WongTY.Handan Eye Study GroupPrevalence and causes of low vision and blindness in a rural chinese adult population: the Handan Eye Study.Ophthalmology2008;115:1965-72

[8] JinZB,HuangXF.Trio-based exome sequencing arrests de novo mutations in early-onset high myopia.Proc Natl Acad Sci U S A2017;114:4219-24 PMCID:PMC5402409

[9] CaiXB,ChenDF,JinZB.An overview of myopia genetics.Exp Eye Res2019;188:107778

[10] WangJ,MuschDC.Progression of myopia in school-aged children after COVID-19 home confinement.JAMA Ophthalmol2021;139:293-300 PMCID:PMC7809617

[11] ZhangX,ChanHN.Myopia incidence and lifestyle changes among school children during the COVID-19 pandemic: a population-based prospective study.Br J Ophthalmol2021:bjophthalmol-2021 PMCID:PMC8359867

[12] BullimoreMA.Myopia control: why each diopter matters.Optom Vis Sci2019;96:463-5

[13] XiaoO,WangD.Distribution and severity of myopic maculopathy among highly myopic eyes.Invest Ophthalmol Vis Sci2018;59:4880-5

[14] YanYN,YangY.Ten-year progression of myopic maculopathy: the beijing eye study 2001-2011.Ophthalmology2018;125:1253-63

[15] FangY,NagaokaN.Progression of myopic maculopathy during 18-year follow-up.Ophthalmology2018;125:863-77

[16] KohV,TanPT.Myopic Maculopathy and optic disc changes in highly myopic young asian eyes and impact on visual acuity.Am J Ophthalmol2016;164:69-79

[17] Ohno-MatsuiK,JonasJB.META-analysis for Pathologic Myopia (META-PM) Study GroupInternational photographic classification and grading system for myopic maculopathy.Am J Ophthalmol2015;159:877-83.e7

[18] YanYN,XuL,WeiWB.Fundus tessellation: prevalence and associated factors: the beijing eye study 2011.Ophthalmology2015;122:1873-80

[19] HayashiK,ShimadaN.Long-term pattern of progression of myopic maculopathy: a natural history study.Ophthalmology2010;117:1595-611, 1611.e1

[20] Ohno-MatsuiK,LaiCC.Updates of pathologic myopia.Prog Retin Eye Res2016;52:156-87

[21] WangNK,ChuHY.Classification of early dry-type myopic maculopathy with macular choroidal thickness.Am J Ophthalmol2012;153:669-77, 677.e1

[22] JonasJB,Panda-JonasS.Bruch’s membrane thickness in high myopia.Acta Ophthalmol2014;92:e470-4

[23] DuR,JonasJB.Clinical features of patchy chorioretinal atrophy in pathologic myopia.Retina2020;40:951-9

[24] Ohno-MatsuiK,SpaideRF.Macular bruch membrane holes in highly myopic patchy chorioretinal atrophy.Am J Ophthalmol2016;166:22-8

[25] JonasJB,SpaideRF,Panda-JonasS.Macular Bruch’s membrane defects and axial length: association with gamma zone and delta zone in peripapillary region.Invest Ophthalmol Vis Sci2013;54:1295-302

[26] YoshidaT,YasuzumiK.Myopic choroidal neovascularization.Ophthalmology2003;110:1297-305

[27] YokoiT.Diagnosis and treatment of myopic maculopathy.Asia Pac J Ophthalmol (Phila)2018;7:415-21

[28] SpaideRF.Choroidal neovascularization in younger patients.Curr Opin Ophthalmol1999;10:177-81

[29] Ohno-MatsuiK,FutagamiS.Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia.Br J Ophthalmol2003;87:570-3 PMCID:PMC1771643

[30] IkunoY,HamasakiT.Ocular risk factors for choroidal neovascularization in pathologic myopia.Invest Ophthalmol Vis Sci2010;51:3721-5

[31] FarinhaCL,NunesSG.Progression of myopic maculopathy after treatment of choroidal neovascularization.Ophthalmologica2014;231:211-20

[32] HayashiK,YoshidaT.Characteristics of patients with a favorable natural course of myopic choroidal neovascularization.Graefes Arch Clin Exp Ophthalmol2005;243:13-9

[33] YoshidaT,OhtakeY.Long-term visual prognosis of choroidal neovascularization in high myopia.Ophthalmology2002;109:712-9

[34] NagaokaN,HayashiW.Characteristics of periconus choroidal neovascularization in pathologic myopia.Am J Ophthalmol2011;152:420-427.e1

[35] LeeDH,LeeSC.Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography.Br J Ophthalmol2018;102:238-42

[36] AvilaMP,JalkhAE,PruettRC.Natural history of choroidal neovascularization in degenerative myopia.Ophthalmology1984;91:1573-81

[37] KojimaA,TeramukaiS.Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.Graefes Arch Clin Exp Ophthalmol2006;244:1474-9

[38] BottoniF.International Ophthalmology;24:249-55.

[39] NeelamK,Ohno-MatsuiK,WongTY.Choroidal neovascularization in pathological myopia.Prog Retin Eye Res2012;31:495-525

[40] McbrienN.Role of the sclera in the development and pathological complications of myopia.Progress in Retinal and Eye Research2003;22:307-38

[41] Ohno-MatsuiK,IshibashiT.Observations of vascular structures within and posterior to sclera in eyes with pathologic myopia by swept-source optical coherence tomography.Invest Ophthalmol Vis Sci2012;53:7290-8

[42] MoriyamaM,FutagamiS.Morphology and long-term changes of choroidal vascular structure in highly myopic eyes with and without posterior staphyloma.Ophthalmology2007;114:1755-62

[43] IshidaT,YokoiT,Ohno-MatsuiK.Possible connection of short posterior ciliary arteries to choroidal neovascularisations in eyes with pathologic myopia.Br J Ophthalmol2019;103:457-62

[44] XieJ,YuJ.Morphologic features of myopic choroidal neovascularization in pathologic myopia on swept-source optical coherence tomography.Front Med (Lausanne)2020;7:615902 PMCID:PMC7785753

[45] GiuffrèC,CarnevaliA,BandelloF.Choroidal neovascularization and coincident perforating scleral vessels in pathologic myopia.Eur J Ophthalmol2017;27:e39-45

[46] QuerquesG,BalaratnasingamC.Lacquer cracks and perforating scleral vessels in pathologic myopia: a possible causal relationship.Am J Ophthalmol2015;160:759-66.e2

[47] WakabayashiT,OshimaY,NishidaK.Aqueous concentrations of vascular endothelial growth factor in eyes with high myopia with and without choroidal neovascularization.J Ophthalmol2013;2013:257381 PMCID:PMC3606763

[48] FerraraN,LeCouterJ.The biology of VEGF and its receptors.Nat Med2003;9:669-76

[49] ShibuyaM.Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.J Biochem Mol Biol2006;39:469-78

[50] NeufeldG,GengrinovitchS.Vascular endothelial growth factor (VEGF) and its receptors.FASEB j1999;13:9-22

[51] SekoY,FujikuraH.Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro.Invest Ophthalmol Vis Sci1999;40:3287-91.

[52] SawadaO,KakinokiM,OhjiM.Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization.Acta Ophthalmol2011;89:459-62

[53] CostagliolaC,dell'OmoR.Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.Br J Ophthalmol2015;99:1004-8

[54] Ohno-MatsuiK,Tombran-TinkJ.Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF.J Cell Physiol2001;189:323-33

[55] Saint-GeniezM,SekiyamaE,D'AmorePA.An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris.Proc Natl Acad Sci U S A2009;106:18751-6 PMCID:PMC2774033

[56] ShinY.J, Nam W.H, Park S.E, Kim J.H, Kim H.K. Aqueous humor concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in high myopic patients.Mol Vis2012;18:2265-70 PMCID:PMC3429358

[57] ChenW,XieS,TangX.Correlation of macular choroidal thickness with concentrations of aqueous vascular endothelial growth factor in high myopia.Curr Eye Res2015;40:307-13

[58] YamamotoY,SasakiS.Associations of inflammatory cytokines with choroidal neovascularization in highly myopic eyes.Retina2015;35:344-50

[59] MartinD,GutkindJS.CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex.J Biol Chem2009;284:6038-42 PMCID:PMC2649103

[60] BianconiV,AtkinSL.The regulation and importance of monocyte chemoattractant protein-1.Curr Opin Hematol2018;25:44-51

[61] LevezielN,ReynoldsR.Genetic factors for choroidal neovascularization associated with high myopia.Invest Ophthalmol Vis Sci2012;53:5004-9 PMCID:PMC3410690

[62] DreismannAK,BarnardAR.Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells.Gene Ther2021;28:265-76 PMCID:PMC8149295

[63] WangQ,LiL.Association between complement factor I gene polymorphisms and the risk of age-related macular degeneration: a Meta-analysis of literature.Int J Ophthalmol2016;9:298-305 PMCID:PMC4761747

[64] FraczekLA.Transcriptional control of genes for soluble complement cascade regulatory proteins.Mol Immunol2010;48:9-13

[65] MiyakeM,NakanishiH.Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes.Invest Ophthalmol Vis Sci2013;54:4208-12

[66] SteeleFR,JohnsonLV.Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family.Proc Natl Acad Sci U S A1993;90:1526-30 PMCID:PMC45907

[67] Tombran-tinkJ,JohnsonLV.PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity.Exp Eye Res1991;53:411-4

[68] KarakousisP.C, John S.K, Behling K.C, et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues.Mol Vis2001;7:154-63

[69] Tombran-tinkJ,ChaderG,BokD.Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity.J Neurosci1995;15:4992-5003 PMCID:PMC6577858

[70] Tombran-TinkJ.PEDF: a multifaceted neurotrophic factor.Nat Rev Neurosci2003;4:628-36

[71] DawsonDW,GillisP.Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.Science1999;285:245-8

[72] CayouetteM,BecerraSP.Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations.Neurobiol Dis1999;6:523-32

[73] WangX,RenY.PEDF protects human retinal pigment epithelial cells against oxidative stress via upregulation of UCP2 expression.Mol Med Rep2019;19:59-74 PMCID:PMC6297793

[74] CaiJ,GrantMB.Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1.J Biol Chem2006;281:3604-13

[75] RennoR.Z, Youssri A.I, Michaud N, Gragoudas E.S, Miller J.W. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization.Invest Ophthalmol Vis Sci2002;43:1574-80

[76] HoTC,ChengHC,ChenSL.Pigment epithelium-derived factor protects retinal pigment epithelium from oxidant-mediated barrier dysfunction.Biochem Biophys Res Commun2006;342:372-8

[77] AmanoS,InagakiY.Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes.Microvasc Res2005;69:45-55

[78] WangY,ShenD,BecerraSP.Pigment epithelium-derived factor reduces apoptosis and pro-inflammatory cytokine gene expression in a murine model of focal retinal degeneration.ASN Neuro2013;5:e00126 PMCID:PMC3840469

[79] Ruiz-MedranoJ,Flores-MorenoI,García-LayanaA.Myopic maculopathy: current status and proposal for a new classification and grading system (ATN).Prog Retin Eye Res2019;69:80-115

[80] Ruiz-MedranoJ,Ohno-MatsuiK,SilvaR.Correlation between atrophy-traction-neovascularization grade for myopic maculopathy and clinical severity.Retina2021;41:1867-73 PMCID:PMC8384244

[81] ChuaWH,ChanYH.Atropine for the treatment of childhood myopia.Ophthalmology2006;113:2285-91

[82] ChiaA,CheungYB.Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).Ophthalmology2012;119:347-54

[83] ChiaA,WenL,GoonYY.Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%.Am J Ophthalmol2014;157:451-457.e1

[84] ChiaA,TanD.Five-Year Clinical Trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops.Ophthalmology2016;123:391-9

[85] ChoP.Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial.Invest Ophthalmol Vis Sci2012;53:7077-85

[86] CharmJ.High myopia-partial reduction ortho-k: a 2-year randomized study.Optom Vis Sci2013;90:530-9

[87] WallineJJ,SinnottLT.Corneal reshaping and myopia progression.Br J Ophthalmol2009;93:1181-5

[88] KakitaT,OshikaT.Influence of overnight orthokeratology on axial elongation in childhood myopia.Invest Ophthalmol Vis Sci2011;52:2170-4

[89] ZhuMJ,HeXG,ZhuJF.The control effect of orthokeratology on axial length elongation in Chinese children with myopia.BMC Ophthalmol2014;14:141 PMCID:PMC4280707

[90] NgDSC,YipFLT.Ranibizumab for myopic choroidal neovascularization.Expert Opin Biol Ther2020;20:1385-93

[91] ZhangM,YanM.KH902 Phase 1 Study GroupA phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011;118:672-8.

[92] RudgeJS,HyltonD.VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.Proc Natl Acad Sci U S A2007;104:18363-70 PMCID:PMC2141784

[93] WolfS,LaganovskaG.RADIANCE Study GroupRADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.Ophthalmology2014;121:682-92.e2

[94] ChenC,HuangZ.The evaluation of a two-year outcome of intravitreal conbercept versus ranibizumab for pathological myopic choroidal neovascularization.Curr Eye Res2020;45:1415-21

[95] Ruiz-MorenoJM,MonteroJA,SilvaR.Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.Br J Ophthalmol2013;97:1447-50

[96] NgDSC,IuLPL.Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization.Expert Opin Drug Saf2022;21:43-54

[97] TufailA,PatelPJ.Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.Ophthalmology2013;120:1944-5.e1

[98] MitchellP,HykinP.ARIES study investigatorsEfficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the aries study: a randomized clinical trial.Retina2021;41:1911-20

[99] KimYC,PakKY.Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema.Sci Rep2020;10:22030 PMCID:PMC7745011

[100] HamiltonRD,MinnellaAM.LUMINOUS study groupReal-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study.PLoS One2020;15:e0227557 PMCID:PMC6974143

[101] LaiTY,LeeGK.Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.Eye (Lond)2012;26:1004-11 PMCID:PMC3396182

[102] CheungCMG,HolzFG.Myopic choroidal neovascularization: review, guidance, and consensus statement on management.Ophthalmology2017;124:1690-711

[103] Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. Ophthalmology 2001;108:841-52.

[104] VirgiliG.Laser photocoagulation for choroidal neovascularisation in pathologic myopia.Cochrane Database Syst Rev2005;:CD004765

[105] IwaseT,RaE,TerasakiH.Changes in choriocapillaris and retinal morphology after laser photocoagulation by OCT angiography: A case report.Medicine (Baltimore)2018;97:e13278 PMCID:PMC6257440

[106] PeceA,AvanzaP,GalliL.Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results.Int Ophthalmol18:339-44

[107] BrancatoR,PeceA,AvanzaP.Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomized study of three different wavelengths.Int Ophthalmol1988;11:235-8

[108] SecrétanM,SoubraneG.Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment.Eur J Ophthalmol1997;7:307-316

[109] BrancatoR,AvanzaP.Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia.Retina1990;10:239-43

[110] Parodi M, La Spina C, Berchicci L, Petruzzi G, Bandello F. Photosensitizers and photodynamic therapy: Verteporfin. in: Nguyen Q, Rodrigues E, Farah M, Mieler W, Do D, editors.Retinal Pharmacotherapeutics. S. Karger AG2015. pp. 330-6

[111] Schlötzer-SchrehardtU,NaumannGO,MichelsS.Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.Graefes Arch Clin Exp Ophthalmol2002;240:748-57

[112] Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. Ophthalmology 2003;110:667-73.

[113] MonteroJA.Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.Br J Ophthalmol2003;87:173-6

[114] KangHM.Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study.Retina2013;33:1613-22

[115] KimYM,KohHJ.The analysis of lacquer crack in the assessment of myopic choroidal neovascularization.Eye (Lond)2011;25:937-46 PMCID:PMC3178161

[116] ZhuY,XuG.Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.Cochrane Database Syst Rev2016;12:CD011160 PMCID:PMC6464015

[117] MMShevelev.Operation against high myopia and scleralectasia with aid of the transplantation of fascia lata on thinned sclera.Russian Oftalmol1930;11:107-10

[118] WEB., AA S. Surgical treatment of high myopia; the combined lamellar scleral resection with scleral reinforcement using donor eye.Trans Am Acad Ophthalmol1958;62:791-802

[119] ThompsonFB.A Simplified scleral reinforcement technique. Am J Ophthalmol 1978;86:782-90.

[120] NesterovAP,SvirinAV.Early and late results of fascia lata transplantation in high myopia.Br J Ophthalmol1976;60:271-2 PMCID:PMC1017490

[121] ChenM,ChuR.The efficacy and safety of modified Snyder-Thompson posterior scleral reinforcement in extensive high myopia of Chinese children.Graefes Arch Clin Exp Ophthalmol2013;251:2633-8

[122] MiaoZ,MengX.Modified posterior scleral reinforcement as a treatment for high myopia in children and its therapeutic effect.Biomed Res Int2019;2019:5185780 PMCID:PMC6362476

[123] DongX,BuJ.The efficacy of modified posterior scleral reinforcement with round scleral patches in Chinese children with high myopia.Graefes Arch Clin Exp Ophthalmol2020;258:1543-7

[124] XueA,ZhengL,ChengL.Posterior scleral reinforcement on progressive high myopic young patients.Optom Vis Sci2014;91:412-8

[125] CurtinB.J. The posterior staphyloma of pathologic myopia.Trans Am Ophthalmol Soc1977;75:67-86 PMCID:PMC1311542

[126] CurtinBJ.Long-term results of scleral reinforcement surgery. Am J Ophthalmol 1987;103:544-8.

[127] WuH,ZhaoF.Scleral hypoxia is a target for myopia control.Proc Natl Acad Sci U S A2018;115:E7091-100 PMCID:PMC6064999

[128] LiuY,XuY,MuG.The influence of the choroid on the onset and development of myopia: from perspectives of choroidal thickness and blood flow.Acta Ophthalmol2021;99:730-8

[129] NicklaDL.Choroidal thickness predicts ocular growth in normal chicks but not in eyes with experimentally altered growth.Clin Exp Optom2015;98:564-70

[130] ZhouX,ZhangG.Increased choroidal blood perfusion can inhibit form deprivation myopia in guinea pigs.Invest Ophthalmol Vis Sci2020;61:25 PMCID:PMC7683853

[131] ZhangZ,WeiW.Investigation of macular choroidal thickness and blood flow change by optical coherence tomography angiography after posterior scleral reinforcement.Front Med (Lausanne)2021;8:658259 PMCID:PMC8130341

[132] FrisinaR,PalmieriM,TozziL.Myopic Traction Maculopathy: Diagnostic and management strategies.Clin Ophthalmol2020;14:3699-708 PMCID:PMC7646438

[133] WardB,MayerMJ.The efficacy and safety of posterior pole buckles in the control of progressive high myopia.Eye (Lond)2009;23:2169-74

[134] LiuB,LiY.Macular buckling using a three-armed silicone capsule for foveoschisis associated with high myopia.Retina2016;36:1919-26

[135] AlkabesM.Macular buckle technique in myopic traction maculopathy: a 16-year review of the literature and a comparison with vitreous surgery.Graefes Arch Clin Exp Ophthalmol2018;256:863-77

[136] ParoliniB,PinackattS.Indications and results of a new l-shaped macular buckle to support a posterior staphyloma in high myopia.Retina2015;35:2469-82

[137] LiuB,LiY.Comparison of macular buckling and vitrectomy for the treatment of macular schisis and associated macular detachment in high myopia: a randomized clinical trial.Acta Ophthalmol2020;98:e266-72 PMCID:PMC7216842

[138] SpoerlE.Techniques for stiffening the cornea.J Refract Surg1999;15:711-3

[139] WollensakG.Collagen crosslinking of human and porcine sclera.J Cataract Refract Surg2004;30:689-95

[140] GawargiousBA,LesgartM,DemerJL.Differential regional stiffening of sclera by collagen cross-linking.Curr Eye Res2020;45:718-25 PMCID:PMC7239705

[141] LiuTX,GuYW,WangZ.Correlation of discoloration and biomechanical properties in porcine sclera induced by genipin.Int J Ophthalmol2014;7:621-5 PMCID:PMC4137195

[142] LinX,DaiJ,QuX.Scleral cross-linking using glyceraldehyde for the prevention of axial elongation in the rabbit: blocked axial elongation and altered scleral microstructure.Curr Eye Res2019;44:162-71

[143] ChoiS,LeeHJ.Structural response of human corneal and scleral tissues to collagen cross-linking treatment with riboflavin and ultraviolet A light.Lasers Med Sci2013;28:1289-96

[144] KrasseltK,BrunnerR,FranckeM.Various cross-linking methods inhibit the collagenase I degradation of rabbit scleral tissue.BMC Ophthalmol2020;20:488 PMCID:PMC7734860

[145] WangM.Effects of scleral cross-linking using genipin on the process of form-deprivation myopia in the guinea pig: a randomized controlled experimental study.BMC Ophthalmol2015;15:89 PMCID:PMC4518847

[146] HannonBG,FeolaAJ.Assessment of visual and retinal function following in vivo genipin-induced scleral crosslinking.Transl Vis Sci Technol2020;9:8 PMCID:PMC7488211

[147] SunM,LiY.Evaluation of the safety and long-term scleral biomechanical stability of UVA cross-linking on scleral collagen in rhesus monkeys.J Refract Surg2020;36:696-702

[148] XueA,TanG.Genipin-crosslinked donor sclera for posterior scleral contraction/reinforcement to fight progressive myopia.Invest Ophthalmol Vis Sci2018;59:3564-73

[149] WeissJN.Stem cell ophthalmology treatment study (SCOTS): bone marrow derived stem cells in the treatment of Usher syndrome.Stem Cell Investig2019;6:31 PMCID:PMC6789203

[150] WeissJN.Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy.Stem Cell Investig2019;6:41 PMCID:PMC6987313

[151] WeissJN,BenesSC.Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of Leber's hereditary optic neuropathy.Neural Regen Res2016;11:1685-94 PMCID:PMC5116851

[152] WeissJN,BenesSC.Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy.Neural Regen Res2015;10:1507-15 PMCID:PMC4625519

[153] WeissJN,LevyS.Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment.Neural Regen Res2016;11:1512-6 PMCID:PMC5090858

[154] JonasJB,Panda-JonasS.Updates on the epidemiology of age-related macular degeneration.Asia Pac J Ophthalmol (Phila)2017;6:493-7

[155] BlasiakJ.Senescence in the pathogenesis of age-related macular degeneration.Cell Mol Life Sci2020;77:789-805

[156] FritscheLG,BaileyJN.A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.Nat Genet2016;48:134-43 PMCID:PMC4745342

[157] KauppinenA,BlasiakJ,KaarnirantaK.Inflammation and its role in age-related macular degeneration.Cell Mol Life Sci2016;73:1765-86 PMCID:PMC4819943

[158] PenningtonKL.Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors.Eye Vis (Lond)2016;3:34 PMCID:PMC5178091

[159] GragoudasES,CunninghamET Jr,GuyerDR.VEGF Inhibition Study in Ocular Neovascularization Clinical Trial GroupPegaptanib for neovascular age-related macular degeneration.N Engl J Med2004;351:2805-16

[160] RicciF,NavarraP,StumppM.Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches.Int J Mol Sci2020;21:8242 PMCID:PMC7662479

[161] TsangSH. Stargardt Disease. In: Tsang SH, Sharma T, editors. Atlas of inherited retinal diseases. Cham: Springer International Publishing; 2018. pp.139-51.

[162] LiewG,BunceC.A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010.BMJ Open2014;4:e004015 PMCID:PMC3927710

[163] TsybovskyY,PalczewskiK.The ATP-Binding Cassette Transporter ABCA4: Structural and Functional Properties and Role in Retinal Disease. In: Lambris JD, Adamis AP, editors. Inflammation and retinal disease: complement biology and pathology. New York: Springer; 2010. pp. 105-25. PMCID:PMC2930353

[164] ZhangK,HanM.A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy.Nat Genet2001;27:89-93

[165] AveldañoMI.Phospholipid species containing long and very long polyenoic fatty acids remain with rhodopsin after hexane extraction of photoreceptor membranes.Biochemistry1988;27:1229-39

[166] SuhM.20:5n-3 but not 22:6n-3 is a preferred substrate for synthesis of n-3 very-long- chain fatty acids (C24-C36) in retina.Curr Eye Res2005;30:959-68

[167] NorrisCE,PereraSMDC.Native mass spectrometry reveals the simultaneous binding of lipids and zinc to rhodopsin.Int J Mass Spectrom2021;460:116477 PMCID:PMC7709953

[168] McMahonA,WoodsAS.A Stargardt disease-3 mutation in the mouse Elovl4 gene causes retinal deficiency of C32-C36 acyl phosphatidylcholines.FEBS Lett2007;581:5459-63 PMCID:PMC2144913

[169] KniazevaM,MorganB.A new locus for autosomal dominant stargardt-like disease maps to chromosome 4.Am J Hum Genet1999;64:1394-9 PMCID:PMC1377876

[170] YangZ,LilloC.Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice.J Clin Invest2008;118:2908-16 PMCID:PMC2483685

[171] SternJ.Retinal pigment epithelial cell proliferation.Exp Biol Med (Maywood)2015;240:1079-86 PMCID:PMC4935281

[172] ZhangH,JiaoL.Transplantation of GMP-grade human iPSC-derived retinal pigment epithelial cells in rodent model: the first pre-clinical study for safety and efficacy in China.Ann Transl Med2021;9:245 PMCID:PMC7940887

[173] SchwartzSD,HeilwellG.Embryonic stem cell trials for macular degeneration: a preliminary report. The Lancet 2012;379:713-20.

[174] XiangP,ZhuY.A novel Bruch’s membrane-mimetic electrospun substrate scaffold for human retinal pigment epithelium cells.Biomaterials2014;35:9777-88

[175] DinizB,ThomasB.Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer.Invest Ophthalmol Vis Sci2013;54:5087-96 PMCID:PMC3726243

[176] daCruz L,GeorgiadisO.Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration.Nat Biotechnol2018;36:328-37

[177] KashaniAH,RahhalFM.A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration.Sci Transl Med2018;10:eaao4097

[178] MandaiM,KurimotoY.Autologous induced stem-cell-derived retinal cells for macular degeneration.N Engl J Med2017;376:1038-46

[179] ZhangCJ,JinZB.The road to restore vision with photoreceptor regeneration.Exp Eye Res2021;202:108283

[180] GolchinA.Biological products: cellular therapy and FDA approved products.Stem Cell Rev Rep2019;15:166-75

[181] ZhangZ,JiangX.Pars plana vitrectomy and wide internal limiting membrane peeling with perfluoropropane tamponade for highly myopic foveoschisis-associated macular hole.Retina2017;37:274-82

[182] ShaoQ,HeussenFM,SunX.Postoperative anatomical and functional outcomes of different stages of high myopia macular hole.BMC Ophthalmol2015;15:93 PMCID:PMC4527123

[183] QuJ,JiangY.Vitrectomy outcomes in eyes with high myopic macular hole without retinal detachment.Retina2012;32:275-80

[184] FangY,ShimadaN.Development of macular atrophy after pars plana vitrectomy for myopic traction maculopathy and macular hole retinal detachment in pathologic myopia.Retina2020;40:1881-93

[185] AlkabesM,NucciP.Anatomical and visual outcomes in high myopic macular hole (HM-MH) without retinal detachment: a review.Graefes Arch Clin Exp Ophthalmol2014;252:191-9

[186] PangCE,FreundKB.Extreme choroidal thinning in high myopia.Retina2015;35:407-15

[187] KeeleyF,VeselyS.Characterization of collagen from normal human sclera. Exp Eye Res 1984;39:533-42.

[188] BooteC,GrytzR,NguyenTD.Scleral structure and biomechanics.Prog Retin Eye Res2020;74:100773 PMCID:PMC7187923

[189] RadaJA,NortonTT.The sclera and myopia.Exp Eye Res2006;82:185-200

[190] ShenL,XuX.Scleral and choroidal volume in relation to axial length in infants with retinoblastoma versus adults with malignant melanomas or end-stage glaucoma.Graefes Arch Clin Exp Ophthalmol2016;254:1779-86

[191] CurtinBJ,RenaldoDP.Normal and staphylomatous sclera of high myopia. An electron microscopic study.Arch Ophthalmol1979;97:912-5

[192] GuggenheimJ.A, McBrien N.A. Form-deprivation myopia induces activation of scleral matrix metalloproteinase-2 in tree shrew.Invest Ophthalmol Vis Sci.1996;37:1380-95

[193] RadaJ.A, Nickla D.L, Troilo D. Decreased proteoglycan synthesis associated with form deprivation myopia in mature primate eyes.Invest Ophthalmol Vis Sci41:2050-8

[194] GabbianiG.The myofibroblast in wound healing and fibrocontractive diseases.J Pathol2003;200:500-3

[195] HinzB,TomasekJJ,ChaponnierC.Alpha-smooth muscle actin expression upregulates fibroblast contractile activity.Mol Biol Cell2001;12:2730-41 PMCID:PMC59708

[196] JoblingAI,MetlapallyR,McBrienNA.Regulation of scleral cell contraction by transforming growth factor-beta and stress: competing roles in myopic eye growth.J Biol Chem2009;284:2072-9

[197] TomasekJJ,HinzB,BrownRA.Myofibroblasts and mechano-regulation of connective tissue remodelling.Nat Rev Mol Cell Biol2002;3:349-63

[198] ShinoharaK,LiuH.Establishment of novel therapy to reduce progression of myopia in rats with experimental myopia by fibroblast transplantation on sclera.J Tissue Eng Regen Med2018;12:e451-61

[199] TsaiCL,FiniME.Identification of multipotent stem/progenitor cells in murine sclera.Invest Ophthalmol Vis Sci2011;52:5481-7 PMCID:PMC3262553

[200] ZvaiflerNJ,AdamsG.Mesenchymal precursor cells in the blood of normal individuals.Arthritis Res2000;2:477-88 PMCID:PMC17820

[201] NakaharaH.In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells*1. Exp Cell Res 1991;195:492-503.

[202] ČamernikK,ZupanJ.Human skeletal muscle-derived mesenchymal stem/stromal cell isolation and growth kinetics analysis. In: Turksen K, editor. Stem Cells and Aging. New York: Springer; 2019. pp. 119-29.

[203] FriedensteinA.J., Gorskaja J.F., Kulagina N.N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs.Exp Hematol1976;4:267-74. [PMID:976387

[204] GronthosS,BrahimJ,ShiS.Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo.Proc Natl Acad Sci U S A2000;97:13625-30 PMCID:PMC17626

[205] WangL,LiS.Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study.Drug Des Devel Ther2019;13:4331-40 PMCID:PMC6930836

[206] In't Anker PS,Kleijburg-vander Keur C.Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation.Blood2003;102:1548-9

[207] In't Anker PS,Kleijburg-vander Keur C.Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta.Stem Cells2004;22:1338-45

[208] MotalnH,LahTT.Human mesenchymal stem cells and their use in cell-based therapies.Cancer2010;116:2519-30

[209] GlennieS,DysonPJ,DazziF.Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.Blood2005;105:2821-7

[210] AggarwalS.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood2005;105:1815-22

[211] CorcioneA,FerrettiE.Human mesenchymal stem cells modulate B-cell functions.Blood2006;107:367-72

[212] BeythS,MevorachD.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood2005;105:2214-9

[213] CaplanAI.Mesenchymal stem cells as trophic mediators.J Cell Biochem2006;98:1076-84

[214] Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells.Cytokine Growth Factor Rev2009;20:419-27

[215] KinnairdT,BurnettMS.Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms.Circulation2004;109:1543-9

[216] SeahI,SooLin Wong D.Retinal pigment epithelium transplantation in a non-human primate model for degenerative retinal diseases.J Vis Exp2021;

[217] LiXJ,LiQM.Posterior scleral reinforcement for the treatment of pathological myopia.Int J Ophthalmol2016;9:580-4 PMCID:PMC4853356

[218] PengC,DingX.Effects of posterior scleral reinforcement in pathological myopia: a 3-year follow-up study.Graefes Arch Clin Exp Ophthalmol2019;257:607-17

[219] ShenZM,ZhangLY,ChuRY.Posterior scleral reinforcement combined with patching therapy for pre-school children with unilateral high myopia.Graefes Arch Clin Exp Ophthalmol2015;253:1391-5

[220] HuH,WuR,FangM.Axial length/corneal radius of curvature ratio assessment of posterior sclera reinforcement for pathologic myopia.Ophthalmologica2018;239:128-32